|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAS |
Gene summary for FAS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAS | Gene ID | 355 |
| Gene name | Fas cell surface death receptor | |
| Gene Alias | ALPS1A | |
| Cytomap | 10q23.31 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P25445 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 355 | FAS | LZE4T | Human | Esophagus | ESCC | 9.35e-06 | 1.19e-01 | 0.0811 |
| 355 | FAS | LZE8T | Human | Esophagus | ESCC | 3.11e-08 | 2.93e-01 | 0.067 |
| 355 | FAS | LZE20T | Human | Esophagus | ESCC | 1.03e-05 | 3.08e-02 | 0.0662 |
| 355 | FAS | LZE22D1 | Human | Esophagus | HGIN | 6.30e-06 | 1.15e-01 | 0.0595 |
| 355 | FAS | LZE22T | Human | Esophagus | ESCC | 4.91e-02 | 2.67e-01 | 0.068 |
| 355 | FAS | LZE24T | Human | Esophagus | ESCC | 1.64e-11 | 2.72e-02 | 0.0596 |
| 355 | FAS | LZE6T | Human | Esophagus | ESCC | 3.85e-03 | 2.03e-01 | 0.0845 |
| 355 | FAS | P2T-E | Human | Esophagus | ESCC | 5.17e-36 | 8.88e-01 | 0.1177 |
| 355 | FAS | P4T-E | Human | Esophagus | ESCC | 7.55e-04 | 2.05e-02 | 0.1323 |
| 355 | FAS | P8T-E | Human | Esophagus | ESCC | 1.93e-19 | 2.75e-01 | 0.0889 |
| 355 | FAS | P9T-E | Human | Esophagus | ESCC | 3.13e-07 | 1.05e-01 | 0.1131 |
| 355 | FAS | P11T-E | Human | Esophagus | ESCC | 5.71e-06 | 3.92e-01 | 0.1426 |
| 355 | FAS | P15T-E | Human | Esophagus | ESCC | 2.41e-06 | 6.38e-02 | 0.1149 |
| 355 | FAS | P16T-E | Human | Esophagus | ESCC | 4.63e-02 | 2.46e-02 | 0.1153 |
| 355 | FAS | P21T-E | Human | Esophagus | ESCC | 3.15e-05 | 1.90e-01 | 0.1617 |
| 355 | FAS | P22T-E | Human | Esophagus | ESCC | 1.01e-03 | -2.44e-02 | 0.1236 |
| 355 | FAS | P23T-E | Human | Esophagus | ESCC | 4.67e-11 | 3.15e-01 | 0.108 |
| 355 | FAS | P24T-E | Human | Esophagus | ESCC | 4.87e-11 | 1.95e-01 | 0.1287 |
| 355 | FAS | P26T-E | Human | Esophagus | ESCC | 2.19e-07 | 9.14e-02 | 0.1276 |
| 355 | FAS | P27T-E | Human | Esophagus | ESCC | 9.86e-04 | 1.08e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
| GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
| hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
| hsa0493230 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
| hsa0513039 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
| hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
| hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
| hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
| hsa0517029 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
| hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
| hsa0516420 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
| hsa0411510 | Esophagus | HGIN | p53 signaling pathway | 21/1383 | 74/8465 | 6.25e-03 | 4.25e-02 | 3.37e-02 | 21 |
| hsa0516330 | Esophagus | HGIN | Human cytomegalovirus infection | 51/1383 | 225/8465 | 7.67e-03 | 4.63e-02 | 3.68e-02 | 51 |
| hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
| hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
| hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
| hsa04932113 | Esophagus | HGIN | Non-alcoholic fatty liver disease | 66/1383 | 155/8465 | 5.21e-15 | 1.21e-13 | 9.64e-14 | 66 |
| hsa05130115 | Esophagus | HGIN | Pathogenic Escherichia coli infection | 54/1383 | 197/8465 | 4.91e-05 | 6.15e-04 | 4.89e-04 | 54 |
| hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
| hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
| hsa04210110 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| FASLG | FAS | FASL_FAS | FASLG | Breast | ADJ |
| FASLG | FAS | FASL_FAS | FASLG | Breast | DCIS |
| FASLG | FAS | FASL_FAS | FASLG | Cervix | ADJ |
| FASLG | FAS | FASL_FAS | FASLG | Cervix | CC |
| FASLG | FAS | FASL_FAS | FASLG | Cervix | Healthy |
| FASLG | FAS | FASL_FAS | FASLG | Cervix | Precancer |
| FASLG | FAS | FASL_FAS | FASLG | Endometrium | ADJ |
| FASLG | FAS | FASL_FAS | FASLG | Endometrium | AEH |
| FASLG | FAS | FASL_FAS | FASLG | Endometrium | EEC |
| FASLG | FAS | FASL_FAS | FASLG | HNSCC | OSCC |
| FASLG | FAS | FASL_FAS | FASLG | THCA | ADJ |
| FASLG | FAS | FASL_FAS | FASLG | THCA | Cancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAS | SNV | Missense_Mutation | c.682N>A | p.Asp228Asn | p.D228N | P25445 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAS | SNV | Missense_Mutation | novel | c.783G>T | p.Glu261Asp | p.E261D | P25445 | protein_coding | tolerated(0.24) | benign(0.047) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| FAS | SNV | Missense_Mutation | c.814N>C | p.Glu272Gln | p.E272Q | P25445 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| FAS | SNV | Missense_Mutation | c.628N>T | p.His210Tyr | p.H210Y | P25445 | protein_coding | tolerated(1) | benign(0.119) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| FAS | SNV | Missense_Mutation | c.793G>C | p.Asp265His | p.D265H | P25445 | protein_coding | deleterious(0.02) | benign(0.136) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAS | SNV | Missense_Mutation | c.781N>A | p.Glu261Lys | p.E261K | P25445 | protein_coding | deleterious(0.01) | possibly_damaging(0.807) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAS | SNV | Missense_Mutation | rs773565107 | c.340N>A | p.Glu114Lys | p.E114K | P25445 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FAS | SNV | Missense_Mutation | c.542T>C | p.Leu181Pro | p.L181P | P25445 | protein_coding | tolerated(0.08) | benign(0.055) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | MPA | PROGESTERONE | 14659903 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ALL-TRANS RETINOIC ACID | 9792441 | ||
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VALPROIC ACID | 16328060 | ||
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CHOLECALCIFEROL | CHOLECALCIFEROL | 9811059 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | TENIPOSIDE | TENIPOSIDE | 9543255 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | VESNARINONE | VESNARINONE | 9226479 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 11437491 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | LITHIUM | LITHIUM | 15475000 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | ASPIRIN | ASPIRIN | 15200494 | |
| 355 | FAS | CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | BISPECIFIC ANTIBODY | 11280736 |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |